Singapore

Singapore has a highly restrictive controlled-drugs regime for classical psychedelics. CNB materials describe psilocybin mushrooms as illegal under the Misuse of Drugs Act, and MDMA is listed as a controlled drug; CNB is the main enforcement authority.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Singapore.

1
Singapore's public-facing policy signal is firmly prohibitionary for classical psychedelics, with CNB explicitly naming psilocybin mushrooms and MDMA in its controlled-drugs materials.
2
The practical clinical pathway in Singapore appears to be ketamine/esketamine rather than psychedelic-assisted therapy with schedule-I-style compounds.
3
Published clinical evidence linked to Singapore in this area is sparse and appears centred on ketamine for depressive disorders, consistent with the database snapshot showing only one linked trial and no active linked trials.
4
Major public institutions such as HSA and CNB are the key gatekeepers, so any future change would likely be visible first through regulator notices rather than informal clinic-led expansion.
5
Available public material suggests a cautious research environment, but not a broad permissive one; there is no strong evidence in the sources reviewed of a domestic psilocybin or MDMA clinical programme moving into routine care.

Research Snapshot

Blossom currently tracks 1 psychedelic clinical trial connected to Singapore.

Active trials: 0
Total trials: 1
Stakeholders: 1
Events: 0

Top Compounds

Ketamine(1)

Medical Access Snapshot

Singapore maintains a highly restrictive statutory regime for classical psychedelics (psilocybin, MDMA, DMT, mescaline, 2C-X, 5-MeO-DMT, ibogaine, ayahuasca), classifying them as controlled substances under the Misuse of Drugs Act and enforced by the Central Narcotics Bureau (CNB). One exception in the therapeutic/regulated product space is esketamine (SPRAVATO®), which is registered by the Health Sciences Authority (HSA) for specific, specialist-administered indications; ketamine itself is a controlled drug but may be used under strict medical...

View trials→View stakeholders→Open access guide→

Regulatory Status

Access is medical-only and tightly restricted. Classical psychedelics such as psilocybin and MDMA are controlled under Singapore's drug laws, with CNB enforcement and penalties for possession, consumption, importation, exportation, trafficking and manufacture; current public materials do not indicate any general legal access pathway for psychedelic-assisted therapy outside approved products or research settings. Ketamine is controlled but may be used under medical supervision, and esketamine is a registered therapeutic product.